Mika Yamauchi
Overview
Explore the profile of Mika Yamauchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
115
Citations
2064
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanaka Y, Soen S, Hirata S, Okada Y, Fujiwara S, Tanaka I, et al.
J Bone Miner Metab
. 2024 Mar;
42(2):143-154.
PMID: 38538869
Introduction: Although synthetic glucocorticoids (GCs) are commonly used to treat autoimmune and other diseases, GC induced osteoporosis (GIOP) which accounts for 25% of the adverse reactions, causes fractures in 30-50%...
2.
Otani H, Notsu M, Yamauchi M, Nawata K, Kanasaki K
Horm Metab Res
. 2023 Apr;
55(9):592-598.
PMID: 37068493
Suppression of TSH levels associated with levothyroxine treatment is a known risk factor for fracture. However, it is unclear whether patients with papillary thyroid carcinoma (PTC) have a higher risk...
3.
Makino H, Notsu M, Asayama I, Otani H, Morita M, Yamamoto M, et al.
Intern Med
. 2022 Apr;
61(22):3383-3390.
PMID: 35370235
Parathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently...
4.
Takedani K, Notsu M, Adachi N, Tanaka S, Yamamoto M, Yamauchi M, et al.
BMC Endocr Disord
. 2021 Oct;
21(1):213.
PMID: 34689780
Background: Thyroid crisis is a life-threatening condition in thyrotoxic patients. Although differentiated thyroid cancer is one of the causes of hyperthyroidism, reports on thyroid crisis caused by thyroid cancer are...
5.
Takedani K, Notsu M, Koike S, Yamauchi M, Mori T, Sohara E, et al.
CEN Case Rep
. 2021 Jan;
10(2):294-300.
PMID: 33398781
Osteomalacia is a systemic metabolic bone disease. Hypophosphatemia is one of the most important causes of impaired mineralization. Here, we describe a case of osteomalacia associated with atypical renal tubular...
6.
Notsu M, Yamauchi M, Sugimoto T, Kanasaki K
Gynecol Endocrinol
. 2020 Sep;
36(12):1140-1143.
PMID: 32954874
Background: The epidemiology and natural history of autonomously functioning thyroid nodules (AFTNs) have not been elucidated. Here we report the pregnant Japanese woman with an AFTN. Case Presentation: The patient...
7.
Yamasaki H, Itawaki A, Morita M, Miyake H, Yamamoto M, Sonoyama H, et al.
BMC Endocr Disord
. 2020 May;
20(1):60.
PMID: 32393233
Background: Non-islet cell tumor hypoglycemia (NICTH) is a rare paraneoplastic syndrome that secretes incompletely processed high molecular weight insulin growth factor 2 (big-IGF2), which results in stimulation of the insulin...
8.
Takedani K, Notsu M, Yamauchi M, Nawata K, Sugimoto T, Kanasaki K
Clin Endocrinol (Oxf)
. 2020 Apr;
93(2):204-211.
PMID: 32324288
Background And Objective: Thyrotoxicosis is associated with accelerated bone turnover and increases the risk of fractures and osteoporosis. Graves' disease is the most common cause of hyperthyroidism. However, studies that...
9.
Yamamoto N, Yamauchi M, Noda T, Matsui Y, Ozaki T
J Orthop Sci
. 2020 Mar;
27(6):1354-1358.
PMID: 32217052
No abstract available.
10.
Notsu M, Yamauchi M, Morita M, Nawata K, Sugimoto T
J Bone Miner Metab
. 2019 Oct;
38(2):264-270.
PMID: 31664535
Introduction: Thyroid-stimulating hormone (TSH)-suppressive therapy is recommended after surgical treatment in high-risk papillary thyroid carcinoma (PTC) patients. TSH-suppressive therapy is a known risk factor for osteoporosis and fractures. However, whether...